<SEC-DOCUMENT>0000885725-24-000081.txt : 20241122
<SEC-HEADER>0000885725-24-000081.hdr.sgml : 20241122
<ACCEPTANCE-DATETIME>20241122161835
ACCESSION NUMBER:		0000885725-24-000081
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		21
CONFORMED PERIOD OF REPORT:	20241119
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241122
DATE AS OF CHANGE:		20241122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BOSTON SCIENTIFIC CORP
		CENTRAL INDEX KEY:			0000885725
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				042695240
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11083
		FILM NUMBER:		241489989

	BUSINESS ADDRESS:	
		STREET 1:		300 BOSTON SCIENTIFIC WAY
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752-1234
		BUSINESS PHONE:		508-683-4000

	MAIL ADDRESS:	
		STREET 1:		300 BOSTON SCIENTIFIC WAY
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752-1234
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bsx-20241119.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:718a6bdc-2f9f-4ecc-8b54-735e7ddf318c,g:e6f73f66-2914-4150-8689-91de50b771f2,d:002366a2a4614e08983bcc93b28d771e-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:bsx="http://www.bostonscientific.com/20241119" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bsx-20241119</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-24">0000885725</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-25">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bsx-20241119.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-19</xbrli:startDate><xbrli:endDate>2024-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-19</xbrli:startDate><xbrli:endDate>2024-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:SeniorNotedue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-19</xbrli:startDate><xbrli:endDate>2024-11-19</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i002366a2a4614e08983bcc93b28d771e_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">_____________________________________________________________________</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">_____________________________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 19, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">BOSTON SCIENTIFIC CORPORATION</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"/><td style="width:31.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.228%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.073%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">1-11083</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">04-2695240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">300 Boston Scientific Way</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Marlborough</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Massachusetts</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">01752-1234</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(Address of principal executive offices)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;             &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;   &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">508</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">683-4000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:1.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.817%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.479%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-17">Common Stock, $0.01 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-18">BSX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-20">0.625% Senior Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-21">BSX27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-23">&#9744;</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i002366a2a4614e08983bcc93b28d771e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.941%"><tr><td style="width:1.0%"/><td style="width:29.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:68.357%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2025 Annual Bonus Plan</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2024, upon the recommendation of the Executive Compensation and Human Resources Committee (the &#8220;Compensation Committee&#8221;), the Board of Directors (the &#8220;Board&#8221;) of Boston Scientific Corporation (the &#8220;Company&#8221;) approved the Company&#8217;s 2025 Annual Bonus Plan effective for the performance year of January 1, 2025 through December 31, 2025 (the &#8220;2025 Annual Bonus Plan&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company&#8217;s overall compensation program, the 2025 Annual Bonus Plan provides an annual cash incentive opportunity for eligible exempt and nonexempt indirect labor or equivalent personnel (including the Company&#8217;s named executive officers meeting the eligibility criteria) based on the achievement of certain performance metrics. The 2025 Annual Bonus Plan is substantially similar to the 2024 annual bonus plan and provides:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for the performance year, a target bonus pool equal to the sum of the bonus targets of all employees who are eligible to participate in the 2025 Annual Bonus Plan;  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">following the end of the performance year, the Compensation Committee shall determine the applicable distribution percentage (between 0% - 150%) of the target bonus pool that will be distributed as bonus for the year, based on the Company&#8217;s performance measured against Company-wide goals for global sales, adjusted earnings per share, and operating income (as a percent of sales), and attainment of environmental, social, and governance (ESG) scorecard goals; provided the Board maintains its discretion to terminate, suspend or modify the 2025 Annual Bonus Plan and to reduce the applicable distribution percentage based on the Company&#8217;s performance relative to its quality objectives and performance of its quality systems; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managers will then assign each plan participant under their management an individual performance modifier (between 0% - 150%) based on such participant&#8217;s performance, which will be used to determine the participant&#8217;s final bonus award, resulting in a maximum payout potential for any individual participant of 0% - 225% of an individual&#8217;s target bonus, consistent with prior annual bonus plan years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards to certain executive officers under the 2025 Annual Bonus Plan are subject to (i) the Company&#8217;s discretionary recoupment policy, which provides that, to the extent permitted by law, the Company may seek reimbursement of a bonus award in the event of an executive officer&#8217;s misconduct or gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company and (ii) the Company&#8217;s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board including in response to the requirements of Section 10D of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), the final rules of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing or as otherwise required by law. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This description of the 2025 Annual Bonus Plan does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such plan. A copy of the 2025 Annual Bonus Plan is included in this filing as Exhibit 10.1 and incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.883%"><tr><td style="width:1.0%"/><td style="width:22.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2025 Performance Share Programs</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2024, upon the recommendation of the Compensation Committee, the Board approved the adoption of two performance share programs, the Boston Scientific Corporation 2025 Relative Total Shareholder Return Performance Share Program (the &#8220;2025 rTSR PSP&#8221;) and the Boston Scientific Corporation 2025 Organic Net Sales Growth Performance Share Program (the &#8220;2025 Organic Net Sales PSP&#8221;). The 2025 rTSR PSP and the 2025 Organic Net Sales PSP are substantially similar to the 2024 Total Shareholder Return Performance Share Program and the 2024 Organic Net Sales Growth Performance Share Program, respectively. These programs represent an important component of the overall mix of the Company&#8217;s long-term incentive program. Under both programs, if the relevant program criteria are met, performance share awards will be granted to the Company&#8217;s executive officers in the form of restricted stock units issued under the Company&#8217;s Amended and Restated 2011 Long-Term Incentive Plan. Awards to certain executive officers under both programs are subject to (i) the Company&#8217;s discretionary recoupment policy, which provides that, to the extent permitted by law, the Company may seek recovery of performance share units in the event of an executive officer&#8217;s misconduct or gross dereliction of duty that results in a material </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">violation of Company policy and causes significant harm to the Company, and (ii) the Company&#8217;s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board including in response to the requirements of Section 10D of the Exchange Act, the final rules of the SEC thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing or as otherwise required by law.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.421%"><tr><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.362%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(A)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2025 Relative Total Shareholder Return Performance Share Program</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the 2025 rTSR PSP is to align the Company&#8217;s executive compensation program with the interests of stockholders and to reinforce the concept of pay for performance by comparing the Total Shareholder Return (&#8220;TSR&#8221;) of the Company&#8217;s common stock to the TSR of the other companies included in the S&amp;P 500 Healthcare Index over a three-year period beginning on January 1, 2025 and ending on December 31, 2027 (the &#8220;Performance Period&#8221;). The number of performance shares awarded will be in a range of 0% to 200% of each participant&#8217;s target number of awards based on the Company&#8217;s TSR rank. Performance share awards will vest only upon satisfaction of both the performance criteria and the payment eligibility criteria set forth in the 2025 rTSR PSP, subject to certain exceptions in the event of a change of control or termination for retirement, death or disability. In the event a participant&#8217;s employment with the Company terminates due to retirement, as defined therein, prior to January 1, 2026, the performance share awards will be forfeited in their entirety.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This description of the 2025 rTSR PSP does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such program. A copy of the 2025 rTSR PSP is included in this filing as Exhibit 10.2 and incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     (B)       2025 Organic Net Sales Growth Performance Share Program</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the 2025 Organic Net Sales PSP is to align the Company&#8217;s executive compensation program with the interests of stockholders and to reinforce the concept of pay for performance by providing incentives for the achievement of key business performance objectives critical to the Company&#8217;s success. Under the 2025 Organic Net Sales PSP, performance will be measured by comparing the Company&#8217;s organic net sales growth, for the three-year period beginning on January 1, 2025 and ending on December 31, 2027 against its financial plan performance for organic net sales, as defined by the 2025 Organic Net Sales PSP. Organic net sales growth, as defined under the 2025 Organic Net Sales PSP, is net sales excluding the impact of foreign currency fluctuation and the impact of acquisitions and divestitures for which there are less than a full period of comparable net sales. The number of performance shares awarded will be in a range of 0% to 200% of each participant&#8217;s target number of awards, depending on such performance. Performance share awards will only vest upon satisfaction of both the performance criteria and the payment eligibility criteria set forth in the 2025 Organic Net Sales PSP, subject to certain exceptions in the event of a change of control or termination for retirement, death or disability. In the event a participant&#8217;s employment with the Company terminates due to retirement, as defined therein, prior to January 1, 2026, the performance share awards will be forfeited in their entirety.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This description of the 2025 Organic Net Sales PSP does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such program. A copy of the 2025 Organic Net Sales PSP is included in this filing as Exhibit 10.3 and incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01             Financial Statements and Exhibits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)          Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit No.         Description</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1*            </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101-2025annualbonusplan.htm">Boston Scientific Corporation 2025 Annual Bonus Plan, effective as of January 1, 2025</a></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2*            </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102-2025tsrplan.htm">Boston Scientific Corporation 2025 Relative Total Shareholder Return Performance Share Program</a></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3*           </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex103-2025organicnetsalesp.htm"> Boston Scientific Corporation 2025 Organic Net Sales Growth Performance Share Program</a></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104               Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*  Documents filed or furnished with this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i002366a2a4614e08983bcc93b28d771e_10"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:8.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.476%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 22, 2024</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BOSTON SCIENTIFIC CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Susan Thompson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Susan Thompson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Chief Corporate Counsel and Assistant Secretary</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101-2025annualbonusplan.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id5c51131cf054e73a93666f4e31ae24b_1"></div><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:40.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2025 Boston Scientific Annual Bonus Plan</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Version&#58; November 2024</font></div></td></tr></table></div></div><div style="padding-right:-4.5pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Establishment and Purpose of the Plan</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Corporation has established the Boston Scientific Corporation Annual Bonus Plan (&#34;Plan&#34;).   As explained in detail below, the Plan basically works as follows. For each Performance Year, there is a Target Bonus Pool, which is the sum of the bonus targets of all employees who are eligible to participate in the Plan for the Performance Year.  After the end of the Performance Year, the Committee determines the Applicable Distribution Percentage of the Target Bonus Pool that will be distributed as bonus for the year, based on the Company&#8217;s performance as to Global Sales, Adjusted Earnings Per Share, Operating Income (as a percent of sales), and its attainment of quality and Environmental, Social, and Governance (ESG) Scorecard goals.  The Applicable Distribution Percentage will be between 0% and 150%. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Management System then allocates the Applicable Distribution Percentage among the managers (resulting in a budget for each manager), who evaluate the performance of the participants under their management and determine for each participant, the percentage of the participant&#8217;s Target Annual Bonus that will be the participant&#8217;s Bonus Award for the Performance Year.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan's purpose is to align the Company's interests and your interests as a Plan participant by providing incentive compensation for the achievement of Company and individual performance objectives. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The capitalized words and terms that are used throughout the Plan are defined in the Glossary in Article IX.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Eligibility and Participation</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You are eligible to participate in the Plan for a Performance Year if you satisfy all of the following eligibility criteria&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You are either a Regular Employee or an Eligible International Employee&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You are not eligible for commissions under any sales compensation plan of the Company (unless the written terms of the plan or program expressly permit participation in both that plan or program and the Plan)&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You are not eligible to participate in any other incentive plan or program of the Company (unless the written terms of that plan or program expressly permit participation in both that plan or program and the Plan)&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You complete at least two full months of Eligible Service during the Performance Year.  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Exempt Employees and Eligible International Employees, if you are eligible to participate in the Plan for only part of the Performance Year (for example, because you change positions or business units during the Performance Year), then you may participate in the Plan on a prorated basis for the Performance Year, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> you complete at least two full months of Eligible Service during the Performance Year.  If you are eligible for prorated participation, the Bonus Award, if any, otherwise payable to you for the Performance Year will be prorated based on your percentage of time in an eligible position during the Performance Year.  This paragraph does not apply to Non-Exempt Employees.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Target Annual Bonus</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exempt Employees and Eligible International Employees&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For each Performance Year in which you are eligible to participate, you will be assigned a Target Annual Bonus, which will be a specified percentage of your annual base salary, determined based on your position.  The Bonus Award, if any, that you ultimately receive for the Performance Year will be a percentage of your Target Annual Bonus, determined pursuant to Article IV. The Target Bonus Pool for a Performance Year will be the sum of the Target Annual Bonuses of all employees who are eligible to participate in the Plan for the Performance Year. All Bonus Awards will be based on your annual base salary and incentive target as of December 31 of the Performance Year.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-exempt employees&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For each Performance Year in which you are eligible to participate, you will be assigned a Target Annual Bonus, which will be a specified percentage of your Total Annual Earnings, determined based on your position.  The Bonus Award, if any, that you ultimately receive for the Performance Year will be a percentage of your Target Annual Bonus, determined pursuant to Article IV. The Target Bonus Pool for a Performance Year will be the sum of the Target </font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:40.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2025 Boston Scientific Annual Bonus Plan</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Version&#58; November 2024</font></div></td></tr></table></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual Bonuses of all employees who are eligible to participate in the Plan for the Performance Year. All Bonus Awards will be based on your annual earnings and incentive target as of December 31 of the Performance Year.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Steps For Determining Bonus Awards</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonus Awards for a Performance Year will be determined pursuant to the following steps&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Step One&#58; Establish performance goals and the Corporate Performance Scale</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or before March 15 of a Performance Year, the Committee will establish performance goals for each of the Plan's Performance Metrics, including quality and ESG Scorecard goals, for the Performance Year.  The Performance Metrics are Global Sales, Adjusted Earnings Per Share and Operating Income (as a percent of Sales).  The Committee will also approve the Corporate Performance Scale for the Performance Year, which will be set forth in a separate schedule.    </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Step Two&#58;  Measure achievement and determine Total Annual Bonus </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the end of the Performance Year, the Committee will evaluate the Company's financial performance results for the Performance Year and determine the extent to which the performance goals were attained.  The Committee will adopt a written resolution as to the extent of the attainment of the performance goals with respect to each of the Performance Metrics.  Based on the extent to which the performance and ESG Scorecard goals were attained, the Chief Executive Officer will make a recommendation to the Committee, consistent with the Corporate Performance Scale, as to the Applicable Distribution Percentage (between 0% and 150%). Taking into account the Chief Executive Officer's recommendation and any other factors that the Committee, in its discretion, deems appropriate, the Committee will approve an Applicable Distribution Percentage for the Performance Year, which must be consistent with the Corporate Performance Scale.  The Committee retains the right to reduce the Applicable Distribution Percentage for the Performance Year based on the Committee's Quality Assessment.      </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Step Three&#58; Determine participants' individual Bonus Awards</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Management System then allocates the Applicable Distribution Percentage among the managers of Plan participants (resulting in a budget for each manager), who evaluate the performance of the participants under their management.  Each manager will determine each participant&#8217;s performance rating as well as the distribution of performance ratings under their management and within their total organization, based on the guidelines established in the system.  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Dynamic Bonus is a portion of the Aggregate Bonus Pool established to help managers better differentiate rewards for the highest performers&#8212;those participants rated &#8220;Outstanding&#8221;&#8212;while recognizing the largest participant population whose performance has been rated &#8220;Successful&#8221; or &#8220;Too New&#8221; and appropriately recognizing lower performers rated &#8220;Improvement Required&#8221; with a lower bonus.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once all the performance ratings have been submitted, managers will assign each participant under their management an Individual Performance Modifier based on their performance rating. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sum of Applicable Distribution Percentage (0% - 150%) multiplied by the Individual Performance Modifier (0% - 150%) will not exceed 225% for any individual participant.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.916%"><tr><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.148%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Annual Base Salary<br>(as of December 31)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">X</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Target Annual Bonus</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">X</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Applicable Distribution Percentage (0% - 150%)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">X</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Individual Performance Modifier<br>(0% - 150%)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#61;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Annual Bonus Plan Award<br>(0% - 225% of Target Annual Bonus)</font></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If participants leave the Company before the Payment Date and, as a result, do not earn their Bonus Awards for the Performance Year, their Bonus Awards will be reallocated by the Chief Executive Officer, in his or her discretion, to other participants who are employed on the Payment Date and will become part of the Bonus Awards paid to those other participants.  As provided in Article V, all Bonus Awards for a Performance Year (including those reallocated pursuant to the previous sentence) will be paid to eligible participants no later than March 15 of the following year.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:40.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2025 Boston Scientific Annual Bonus Plan</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Version&#58; November 2024</font></div></td></tr></table></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Payment Conditions</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Date and Form of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Bonus Awards in the United States will be made by March 15 of the year following the Performance Year for which the Bonus Awards are made. Bonus Awards outside the United States will be processed as soon as administratively possible in each region following the end of the Performance Year and after the Committee has adopted its written resolution as to the attainment of performance goals pursuant to Article IV.  Your Bonus Award, if any, will be paid in a single lump sum payment.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Required Employment on the Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except as otherwise expressly provided in this Article V, to be eligible to receive payment of any Bonus Award, you must be employed by the Company on the Payment Date for that Bonus Award.  In other words, except as expressly provided in this Article V, if you cease employment with Boston Scientific Corporation and all of its Affiliates before the Payment Date, you will not be eligible to receive any Bonus Award that would otherwise have been payable to you if you had been a Company employee on that date.  Conversely, if you are an employee of the Company on the Payment Date, you will be entitled to your Bonus Award, if any, even if you are not actively performing duties on that date.  For example, if you are not required to report to work during a notification period applicable under a Company severance or separation plan, but you are still a Company employee during that period, and the Payment Date occurs during your notification period, you will remain eligible to receive your Bonus Award.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exception Under Written Company Plan or Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If you are specifically exempted, under a written Company plan or agreement, from the requirement to be employed on the Payment Date, you may remain eligible for payment of your Bonus Award, depending on the terms of the applicable written plan or agreement.  In such cases, the terms of such written plan or agreement will govern in all respects.      </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Layoff</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Also, notwithstanding any other provision of the Plan, if you are a participant and your employment ceases prior to the Payment Date by reason of Layoff, you may be eligible for payment of part or all of your Bonus Award, depending on the terms and conditions of the applicable severance pay plan, if any, for the country in which you are employed at the time of layoff. In the event that there is no country-specific severance plan for the country in which you are employed at the time of your Layoff, applicable law will apply.  In the event a previously eligible participant is re-hired within the Performance Year after a layoff and meets the eligibility criteria, if the participant was paid out a pro-rated bonus at the time of severance, then the payout period will not be bridged. If the rehired participant did not receive a pro-rated bonus payout at the time of severance, then the payout period will be bridged, and participant will receive a pro-rated Bonus Award for the Performance Year. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Also, notwithstanding any other provision of the Plan, if you are a participant on a paid leave of absence, you are bonus eligible as long as you meet performance expectations during the Performance Year. Your Bonus Award will be made on the payment date within the applicable country. If you are a participant on an unpaid leave of absence, your Bonus Award, if any, will be pro-rated if the unpaid leave is longer than a continuous six (6) months in duration during the Performance Year. Country specific regulations regarding leaves of absence and bonus eligibility supersede this Plan document.     </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Also notwithstanding any other provision of the Plan, if you are a participant for a Performance Year and your employment ceases due to Retirement prior to the Payment Date for a Bonus Award but after September 30 of the Performance Year to which the Bonus Award pertains, and you had at least nine months of Eligible Service in the Performance Year, you will be entitled to a prorated portion of the Bonus Award, if any, that would otherwise be paid you for the Performance Year. In such a case, proration will be based on the percentage of time in the Performance Year during which you were employed and eligible to participate in the Plan.  The prorated Bonus Award, if any, will be paid on the Payment Date.  For purposes of this paragraph, your employment ceases due to &#8220;Retirement&#8221; if, as of the date of your cessation of employment, (1) you had attained age 55, (2) you had accrued at least five years of service with the Company and (3) the sum of your age and years of service as of your date of cessation of employment equals or exceeds 65.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  For Exempt Employees and Eligible International Employees, if your employment ceases prior to the Payment Date by reason of your death, but you otherwise met all eligibility criteria specified in Article II, your estate may receive a prorated portion of the Bonus Award, if any, that would have been paid had you lived to the Payment Date.  In such a case, proration </font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:40.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2025 Boston Scientific Annual Bonus Plan</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Version&#58; November 2024</font></div></td></tr></table></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be based on the percentage of time in the Performance Year during which you were employed and eligible to participate in the Plan.  The prorated Bonus Award, if any, will be paid on the Payment Date.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Non-Exempt employees, if your employment ceases prior to the Payment Date by reason of your death, but you otherwise met all eligibility criteria specified in Article II, your estate will receive your Bonus Award, if any, that would have been paid had you lived to the Payment Date.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustment for Changes in Standard Hours</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Also notwithstanding any other provision of the Plan, if you are an Exempt Employee or Eligible International employee participant and have a change in standard hours (part-time to full-time, full-time to part-time) during a Performance Year, your Bonus Award, if any, for the Performance Year will be calculated as follows&#58;  Target Annual Bonus percentage multiplied by the average annualized base salary for each period of employment at a specific salary divided by the percentage of the year during which that salary was earned.  For example, if your Target Annual Bonus percentage is 10% and you worked full-time for six (6) months at an annual base salary of 100,000 and moved to a part-time arrangement for the remaining (6) months at an annual base salary of 50,000, your bonus award, if any, would be 7,500.  &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">0.10 x (100,000 x 0.50) &#61; 5,000&#93; and &#91;0.10 x (50,000 x 0.50) &#61; 2,500&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This paragraph does not apply to Non-Exempt Employee participants.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Guarantee of a Bonus Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Nothing in this Plan guarantees that any Bonus Award will be made to any individual.  Receipt of a Bonus Award in one year does not guarantee eligibility in any future year.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Incentive Compensation Recoupment Policy</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To the extent permitted by governing law, the Board, in its discretion, may seek reimbursement of a Bonus Award paid to you if you are a Current Executive Committee Member or Former Executive Committee Member and, in the judgment of the Board, you, while serving in capacity as a Current Executive Committee Member, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company. Further, in such case&#58;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if you are a Current Executive Committee Member, the Board may seek reimbursement of all or a portion of the Bonus Award paid to you during the one-year period preceding the date on which such misconduct or dereliction of duty was discovered by the Company, or</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if you are a Former Executive Committee Member, the Board may seek reimbursement of all or a portion of the Bonus Award paid to you during the one-year period preceding the last date on which you were a Current Executive Committee Member. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recoupment Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Bonus Awards and any compensation associated therewith are subject to forfeiture, recovery by the Company or other action pursuant to any compensation recovery policy adopted by the Board or the Committee in effect from time to time, which includes but is not limited to the Company&#8217;s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board or the Committee including in response to the requirements of Section 10D of the Securities Exchange Act of 1934, as amended, the U.S. Securities and Exchange Commission&#8217;s final rules thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing or as otherwise required by law.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Termination, Suspension, or Modification and Interpretation of the Plan</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board may terminate, suspend or modify (and if suspended, may reinstate with or without modification) all or part of the Plan at any time, with or without notice to participants. The Committee has sole authority over administration and interpretation of the Plan, and the Committee retains its right to exercise discretion as it sees fit. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee reserves the exclusive right to determine eligibility to participate in this Plan and to interpret all applicable terms and conditions, including eligibility criteria, performance objectives and payment conditions, for the Company's executive officers.  The Committee delegates to the Company&#8217;s highest human resources officer the authority to administer, and determine eligibility to participate in, the Plan and interpret all applicable terms and conditions, for employees who are </font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:40.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2025 Boston Scientific Annual Bonus Plan</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Version&#58; November 2024</font></div></td></tr></table></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not executive officers of the Company. The determinations and interpretations of the Committee and its delegates will be conclusive.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Bonus Awards are paid from the Company's general assets. No trust, account or other separate collection of amounts will be established for the payment of Bonus Awards under the Plan. Bonus Awards are unfunded obligations of the Company, so if and when a Bonus Award becomes due, a participant's rights to payment are no greater than the rights of a general unsecured creditor.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Other</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This document sets forth the terms of the Plan and is not intended to be a contract or employment agreement between you or any other participant and the Company. As applicable, it is understood that both you and the Company have the right to terminate your employment with the Company at any time, with or without cause and with or without notice, in acknowledgement of the fact that your employment relationship with the Company is &#8220;at will.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Glossary</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in the Plan, the following words and terms, when capitalized, have the following meanings&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjusted Earnings Per Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a Performance Year, Adjusted Net Income (loss) divided by weighted average shares outstanding for the Performance Year (determined in accordance with generally accepted accounting principles).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjusted Net Income (loss)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> equals the Company's GAAP Net Income (loss)  excluding certain charges (credits) from GAAP net income, including, but not limited to, amortization expense, goodwill and intangible asset impairment charges, acquisition- and divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), certain investment impairment losses (gains), EU Medical Device Regulation implementation charges, pension termination charges, debt extinguishment charges and discrete tax items. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means any corporation, trust, partnership, or any other entity that is considered to be a single employer with Boston Scientific Corporation under Code sections 414(b), (c), (m), or (o), such as a wholly-owned (or at least 80%-owned) subsidiary of Boston Scientific Corporation.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Aggregate Bonus Pool</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, the Target Bonus Pool multiplied by the Applicable Distribution Percentage and modified by the Dynamic Bonus within the Compensation Management System.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Bonus Plan Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a participant for a Performance Year, the annual incentive bonus, if any, payable to the participant for the Performance Year, subject to the terms and conditions of the Plan.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Distribution Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a Performance Year, a percentage, determined by the Committee in accordance with the Corporate Performance Scale, which is between 0% and no more than 150%.  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Board of Directors of Boston Scientific Corporation.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Chief Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Chief Executive Officer of Boston Scientific Corporation.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Internal Revenue Code of 1986, as amended, and its interpretive rules and regulations.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Executive Compensation and Human Resources Committee of the Board.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means Boston Scientific Corporation and its Affiliates.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:40.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2025 Boston Scientific Annual Bonus Plan</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Version&#58; November 2024</font></div></td></tr></table></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation Management System </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means the software tool used by the Company for various compensation management purposes.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Performance Scale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a Performance Year, the schedule used to determine, based on the extent of attainment of the performance goals for the Performance Year, the Applicable Distribution Percentage </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Executive Committee Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means any individual currently designated as a corporate officer of the Company who is in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dynamic Bonus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means the portion of the Aggregate Bonus Pool that is modified when participants' Individual Performance Modifiers are input into the Compensation Management System.  The Dynamic Bonus for a Performance Year shall not exceed 10% of the Target Bonus Pool for the Performance Year.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Eligible International Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an international, international operations, or expatriate employee of the Company working in a position designated by the Company as eligible to participate in the Plan.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Eligible Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means periods in which you are considered, under the rules and procedures of the Company, to be in active service as a Regular Employee or Eligible International Employee (including, but not limited to, time away from work for approved vacation, recognized holidays, and FMLA leave).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental, Social and Governance (ESG) Scorecard </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means, with respect to a Performance Year, performance against global gender and US (inclusive of Puerto Rico) multicultural goals, Engagement goals, and performance against annual environmental goals that are aligned with the Company&#8217;s environmental strategic plan goals.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Executive </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Committee Member means any Current Executive Committee Member or Former Executive Committee Member.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exempt Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an employee of the Company who is on the Company's United States payroll and (1) classified by the Company as a regular full-time or regular part-time Employee&#59; (2) performs a job that the Company has determined to be exempt from the minimum wage and overtime requirements of the Fair Labor Standards Act of 1938, as amended (FLSA)&#59; and (3) is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> any of the following&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">classified by the Company as an intern, summer student, co-op employee, or similar short-term employee&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">classified by the Company as a consultant, temporary or defined-term employee (such as temporary fellowship program employees), or similar category of limited-term employment, regardless of their work schedule or number of hours worked.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Former Executive Committee Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means any individual previously (but not currently) designated as a corporate officer of the Company who was in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Global Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for purposes of the Annual Bonus Plan measures sales using constant currency rates and excludes acquisitions and divestitures not included in the annual operating plan.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Individual Performance Modifier </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means, with respect to a Performance Year, the percentage assigned by a participant&#8217;s manager based on such participant&#8217;s performance rating for the Performance Year.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Layoff</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means a layoff or similar involuntary termination from employment that renders you eligible for severance pay under a Company severance plan or applicable law.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Exempt Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an employee of the Company who is on the Company's United States payroll and (1) classified by the Company as a regular full-time or regular part-time Employee&#59; and (2) performs a job that the Company has determined to be non-exempt from the minimum wage and overtime requirements of the Fair Labor Standards Act of 1938, as amended (FLSA).</font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:40.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2025 Boston Scientific Annual Bonus Plan</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Version&#58; November 2024</font></div></td></tr></table></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Income (as a percent of Sales) means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the company&#8217;s revenue less cost of goods sold less operating expenses, adjusted for certain items consistent with those used to determine the company&#8217;s adjusted earnings per share. These adjustment items include amortization expense, goodwill and other intangible asset impairments, acquisition&#47;divestiture-related net charges (credits), restructuring and restructuring-related net credits, certain litigation-related net charges (credits), and EU MDR implementation costs.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a Performance Year, the date on which Bonus Awards for the Performance Year are paid to participants, which will be no later than March 15 of the following year.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance Metrics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means Global Sales, Adjusted Earnings Per Share, and Operating Income (as a percent of Sales).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for all metrics except environmental metrics, means the 12-month period beginning on January 1 and ending on the following December 31. For the environmental metrics, the 12-month period beginning October 1 2024 and ending on the following September 30, 2025.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Boston Scientific Annual Bonus Plan, which is set forth in this document, as it may be amended from time to time.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Quality Assessment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the process undertaken by the Committee following the end of each Performance Year, to evaluate the Company's progress made toward achievement of its quality objectives and the performance of the Company-wide quality system.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regular Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an employee of the Company who is on the Company's United States payroll and is considered an Exempt Employee or Non-Exempt Employee. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Retirement has the meaning given in Section V in the paragraph entitled &#8220;Retirement.&#8221;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Target Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has the meaning given to that term in Article III.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Target Bonus Pool means,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with respect to a Performance Year, the sum of the Target Annual Bonuses of all employees who are eligible to participate in the Plan for the Performance Year. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Total Annual Earnings </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means, for a Non-Exempt Employee, total annual earnings including regular pay, shift differentials, overtime, vacation, holiday pay, sick hour earnings, and pay during maternity, bonding, sabbatical and disability leave.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex102-2025tsrplan.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2c7ecdb8be20465eabde13cc2d3ea198_1"></div><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.721%"><tr><td style="width:1.0%"></td><td style="width:34.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="image3a.jpg" src="image3a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Relative Total Shareholder Return Performance Share Program (&#8220;rTSR Program&#8221;)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1, 2025 - December 31, 2027</font></div></td></tr></table></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Performance Share Units </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the rTSR Program is to align Boston Scientific&#8217;s executive compensation program with the interests of shareholders and to reinforce the concept of pay for performance by comparing the Total Shareholder Return of shares of Boston Scientific Common Stock (the &#8220;Common Stock&#8221;) to the TSR of companies included in the S&#38;P 500 Healthcare Index over a three-year period beginning on January 1, 2025.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rTSR Program entails the grant of Restricted Stock Units, and the program shall be administered, under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;2011 LTIP&#8221;).  Terms not defined in this rTSR Program document but defined in the 2011 LTIP shall have the same meaning as in the 2011 LTIP.  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Eligible Participants</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rTSR Program covers members of the Executive Committee on the date that awards are granted under the rTSR Program as determined and, in the amounts, established by the Executive Compensation and Human Resources Committee of the Board of Directors (the &#8220;Committee&#8221;).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Performance Share Units</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restricted Stock Units awarded under the rTSR Program (the &#8220;Performance Share Units&#8221;) shall vest only upon satisfaction of both the performance criteria described in this Section III and the payment eligibility criteria described in Section VII.  The applicable performance criteria are based on the TSR of the Common Stock relative to the TSR of companies in the S&#38;P 500 Healthcare Index.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TSR for Boston Scientific and all other companies in the S&#38;P 500 Healthcare Index will be measured over a three-year period beginning January 1, 2025 and ending on December 31, 2027 (the &#8220;Performance Period&#8221;). </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Performance Share Units as to which the performance criteria under this rTSR Program shall be determined to have been satisfied will be in a range of 0% to 200% of the target number of Performance Share Units awarded to the participant as follows&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.694%"><tr><td style="width:1.0%"></td><td style="width:48.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">rTSR Performance<br>Percentile Rank</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Share Units as a Percent of Target</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">75th Percentile or above</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">200%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">55th Percentile</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">100%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">25th Percentile</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">30%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Below 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Percentile</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0%</font></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the minimum level of performance is achieved, the number of Performance Share Units will be calculated linearly between each set of data points. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the end of the Performance Period, the Committee shall determine the number of Performance Share Units as to which the performance criteria of this program have been satisfied, which determination shall be final and binding. Shares of Common Stock will be delivered or otherwise made available to the participant no later than March 15, 2028 in settlement of the Performance Share Units as to which the performance criteria of this program have been satisfied if and to the extent the payment eligibility criteria of Section VII below are also satisfied.  Any Performance Share Units as to which the performance criteria of this Section III have not been satisfied will be forfeited in their entirety.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Calculation of Total Shareholder Return and Definitions</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TSR for Boston Scientific and each other company in the S&#38;P 500 Healthcare Index shall include any cash dividends paid during the Performance Period and shall be determined as follows&#58;</font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.721%"><tr><td style="width:1.0%"></td><td style="width:34.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="image3a.jpg" src="image3a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Relative Total Shareholder Return Performance Share Program (&#8220;rTSR Program&#8221;)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1, 2025 - December 31, 2027</font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Shareholder Return for the Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#61; </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Change in Stock Price + Dividends Paid) &#47; Beginning Stock Price</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Beginning Stock Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the daily average closing price as quoted on the New York Stock Exchange or the NASDAQ Global Select Market, as applicable, of one (1) share of common stock for the two calendar months </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">prior</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the beginning of the Performance Period. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Stock Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the difference between the Beginning Stock Price and the Ending Stock Price.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends Paid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the total of all cash dividends paid on one (1) share of stock during the Performance Period.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ending Stock Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the daily average closing price as quoted on the New York Stock Exchange or the NASDAQ Global Select Market, as applicable, of one (1) share of common stock for the last two calendar months of the Performance Period.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Example&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Beginning Stock Price for a company was $25.00 per share, and the company paid $2.50 in dividends over the Performance Period, and the Ending Stock Price was $30.00 per share (thereby making the Change in Stock Price $5.00 ($30.00 minus $25.00)), then the TSR for that company would be thirty percent (30%).  The calculation is as follows&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#61; ($5.00 + $2.50) &#47; $25.00</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Calculation of Percentile Performance</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the calculation of the TSR for the Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Boston Scientific and each of the other companies in the S&#38;P 500 Healthcare Index, Boston Scientific and the other companies in the S&#38;P 500 Healthcare Index will be ranked, in order of maximum to minimum, according to their respective TSR for the Performance Period.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After this ranking, the percentile performance of Boston Scientific as compared to the other companies in the S&#38;P 500 Healthcare Index shall be determined by the following formula&#58;</font></div><div style="padding-left:36pt;text-align:justify"><img alt="image5a.jpg" src="image5a.jpg" style="height:88px;margin-bottom:5pt;vertical-align:text-bottom;width:217px"></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;P&#8221; represents the percentile performance which will be rounded, if necessary, to the nearest whole percentile by application of standard scientific rounding conventions. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;N&#8221; represents the number of companies in the S&#38;P 500 Healthcare Index, including Boston Scientific.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;R&#8221; represents Boston Scientific&#8217;s ranking versus the other companies in the S&#38;P 500 Healthcare Index. </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Example&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Boston Scientific ranked 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> out of 54 companies, the performance (&#8220;P&#8221;) therefore will be in the 83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentile.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This calculation is as follows&#58;               </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#61; 1 &#8211; (10 &#8211; 1) &#47; (54 &#8211; 1)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">S&#38;P 500 Healthcare Index </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The companies currently included in the S&#38;P 500 Healthcare Index can be found in Appendix A attached hereto.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only companies in the S&#38;P 500 Healthcare Index for an entire Performance Period will be used to determine the TSR percentile rank. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.721%"><tr><td style="width:1.0%"></td><td style="width:34.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="image3a.jpg" src="image3a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Relative Total Shareholder Return Performance Share Program (&#8220;rTSR Program&#8221;)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1, 2025 - December 31, 2027</font></div></td></tr></table></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If two companies in the S&#38;P 500 Healthcare Index merge, the surviving company shall remain in the S&#38;P 500 Healthcare Index.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a company in the S&#38;P 500 Healthcare Index merges with, or is acquired by, a company that is not in the S&#38;P 500 Healthcare Index, and the company in the S&#38;P 500 Healthcare Index is the surviving company, then the surviving company shall be included in the S&#38;P 500 Healthcare Index.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a company in the S&#38;P 500 Healthcare Index merges with, or is acquired by, a company that is not in the S&#38;P 500 Healthcare Index, and the company in the S&#38;P 500 Healthcare Index is not the surviving company or the surviving company is no longer publicly traded, then the surviving company shall not be included in the S&#38;P 500 Healthcare Index.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if a company in the S&#38;P 500 Healthcare Index ceases to be listed in the Healthcare Sector under the Standard &#38; Poor&#8217;s Global Industry Classification Standard (GICS) at any time during the Performance Period (including after a merger, acquisition or other business transaction described above), then it shall not be included in the S&#38;P 500 Healthcare Index. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Payment Eligibility Criteria</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth below with respect to a Change in Control, no Performance Share Units shall vest prior to the end of the Performance Period (December 31, 2027). </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with Boston Scientific and its Affiliates (the &#8220;Company&#8221;) terminates before the last day of the Performance Period, all of his or her Performance Share Units shall be forfeited in their entirety except as set forth below.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants on military, sick or other bona fide leave of absence on December 31, 2027 will not be deemed to have terminated employment with the Company if such absence does not exceed 180 days or, if longer, the period the participant retains the right by statute or by contract to return to employment with the Company. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of any separate Change in Control or similar agreement to which a participant is bound, if there is a Change in Control after December 31, 2025 but before the end of the Performance Period, shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have been satisfied using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2027, as determined by the Committee immediately prior to the consummation of the Change in Control.  Such issuance shall occur within 70 days of the effective date of the Change in Control, on a prorated basis.  The number of shares to be issued on a prorated basis shall be determined as follows&#58; (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months during the Performance Period, rounded up to the nearest whole month&#47;36)).  The number of prorated shares to be issued to the participant, if any, will be approved by the Committee at its next regular meeting.  In the event a Change in Control occurs prior to January 1, 2026, the Performance Share Units will be forfeited in their entirety.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with the Company terminates due to Retirement after December 31, 2025 but before the end of the Performance Period, the participant will continue to be eligible to vest in a pro rated number of Performance Share Units and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have been satisfied at the end of the Performance Period, but no later than March 15, 2028, on a prorated basis using the effective date of the participant&#8217;s termination of employment. The number of shares to be issued on a prorated basis shall be determined as follows&#58; (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months worked during the Performance Period, rounded up to nearest whole month) &#47; 36)).  The number of prorated shares, if any, to be issued to the participant will be approved by the Committee at its regular meeting next following the date of the participant&#8217;s employment termination. In the event a participant&#8217;s employment with the Company terminates due to Retirement prior to January 1, 2026, the Performance Share Units will be forfeited in their entirety.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with the Company terminates due to death or Disability before the end of the Performance Period, the participant will continue to be eligible to vest in all of his or her Performance Share Units and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have </font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.721%"><tr><td style="width:1.0%"></td><td style="width:34.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="image3a.jpg" src="image3a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Relative Total Shareholder Return Performance Share Program (&#8220;rTSR Program&#8221;)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1, 2025 - December 31, 2027</font></div></td></tr></table></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">been satisfied at the end of the Performance Period, but no later than March 15, 2028. The number of shares, if any, to be issued to the participant will be approved by the Committee at its regular meeting next following the date of the participant&#8217;s employment termination. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Termination, Suspension or Modification and Interpretation of the rTSR Program</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee has sole authority over administration and interpretation of the rTSR Program.  The Committee hopes and expects to continue the program in effect but retains its right to exercise discretion as it sees fit, including to prospectively terminate, suspend or modify the rTSR program or criteria for eligible participation in future years.  If suspended, the Committee may reinstate with or without modification all or part of the rTSR Program or criteria for eligible participation&#59; However, no amendment of the Program after the grant date may materially and adversely impair a participant&#8217;s rights under awards made pursuant to the rTSR Program without the participant&#8217;s consent unless the amendment is necessary or desirable to facilitate compliance with applicable law, as determined in the sole discretion of the Committee.  The Committee reserves the exclusive right to determine eligibility to participate in this rTSR Program and to interpret all applicable terms and conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Recoupment Policy</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  To the extent permitted by governing law, the Board, in its discretion, may seek Recovery of Performance Share Units granted to a Current Executive Committee Member or Former Executive Committee Member if, in the judgment of the Board, such Executive Committee Member, while serving in capacity as a Current Executive Committee Member, commits misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The following terms shall have the meaning set forth below&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)         &#34;Current Executive Committee Member&#34; means any individual currently designated as a corporate officer of the Company who is in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)          &#34;Executive Committee Member&#34; means any Current Executive Committee Member or Former Executive Committee Member.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)          &#34;Former Executive Officer&#34; means any individual previously (but not currently) designated as a corporate officer of the Company who was in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)          &#34;Recovery&#34; means the forfeiture or cancellation of unvested Performance Share Units.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recoupment Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Performance Share Units and any compensation associated therewith are subject to forfeiture, recovery by the Company or other action pursuant to any compensation recovery policy adopted by the Board or the Committee in effect from time to time, which includes but is not limited to the Company&#8217;s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board or the Committee including in response to the requirements of Section 10D of the Securities Exchange Act of 1934, as amended, the U.S. Securities and Exchange Commission&#8217;s final rules thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing or as otherwise required by law. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Other</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This document sets forth the terms of the rTSR Program and is not intended to be a contract or employment agreement between the participant and the Company.  As applicable, it is understood that both the participant and the Company have the right to terminate the participant&#8217;s employment with the Company at any time, with or without cause and with or without notice, in acknowledgement of the fact that their employment relationship is &#8220;at will.&#8221; </font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.721%"><tr><td style="width:1.0%"></td><td style="width:34.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="image3a.jpg" src="image3a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Relative Total Shareholder Return Performance Share Program (&#8220;rTSR Program&#8221;)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1, 2025 - December 31, 2027</font></div></td></tr></table></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent section 409A of the Internal Revenue Code (&#8220;Code&#8221;) applies to any award under this rTSR Program, the award shall be interpreted in a manner consistent with Code section 409A.  Where section 409A applies, in the case of any payment made on termination of employment, a termination of employment shall not be deemed to have occurred unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code section 409A and, for purposes of any such provision, references to a &#8220;termination,&#8221; &#8220;termination of employment,&#8221; or like terms shall mean &#8220;separation from service.&#8221;  Where section 409A applies, in the case of a payment made upon a Change in Control, a Change in Control shall not be deemed to have occurred unless there is a change in the ownership or effective control of Boston Scientific, or in the ownership of a substantial portion of the assets of Boston Scientific, as defined in Code section 409A.  Where required by section 409A in the case of a specified employee (as determined under Code section 409A), payments on termination shall be made on the first business day of the seventh month following termination.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2c7ecdb8be20465eabde13cc2d3ea198_58"></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:34.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="image3a.jpg" src="image3a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Relative Total Shareholder Return Performance Share Program (&#8220;rTSR Program&#8221;)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1, 2025 - December 31, 2027</font></div></td></tr></table></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Executive LTIP Program</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">S&#38;P 500 Healthcare Index as of October 15, 2024 &#8211; 62 Companies </font></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.583%"><tr><td style="width:1.0%"></td><td style="width:42.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c5d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Company Name</font></td><td colspan="3" style="background-color:#c5d9f1;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Company Name</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Abbott Laboratories</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Insulet Corporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AbbVie Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Intuitive Surgical, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Agilent Technologies, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IQVIA Holdings Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Align Technology, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Johnson &#38; Johnson</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amgen, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Labcorp Holdings Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Baxter International Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">McKesson Corporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Becton, Dickinson and Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Medtronic plc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Biogen Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Merck &#38; Co., Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bio-Techne Corporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mettler-Toledo International Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Boston Scientific Corporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moderna, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bristol-Myers Squibb Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Molina Healthcare, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cardinal Health, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pfizer Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Catalent, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quest Diagnostics Incorporated</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cencora, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Regeneron Pharmaceuticals, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Centene Corporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ResMed Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Charles River Laboratories International, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revvity, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CVS Health Corporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solventum Corporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Danaher Corporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">STERIS plc</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DaVita Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stryker Corporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DexCom, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Teleflex Incorporated</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Edwards Lifesciences Corporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Cigna Group</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Elevance Health, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Cooper Companies, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eli Lilly and Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Thermo Fisher Scientific Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">GE HealthCare Technologies Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">UnitedHealth Group Incorporated</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Gilead Sciences, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Universal Health Services, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HCA Healthcare, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vertex Pharmaceuticals Incorporated</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Henry Schein, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Viatris Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Hologic, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Waters Corporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Humana Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">West Pharmaceutical Services, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IDEXX Laboratories, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Zimmer Biomet Holdings, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Incyte Corporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Zoetis Inc.</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ex103-2025organicnetsalesp.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie2d4379d35034ffebd1120ab83ce004c_1"></div><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"></td><td style="width:34.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="image1a.jpg" src="image1a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Organic Net Sales Growth Performance Share Program</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(&#8220;ONSG Program&#8221;)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1, 2025 - December 31, 2027</font></div></td></tr></table></div></div><div style="text-align:right"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Purpose of the ONSG Program</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the ONSG Program is to align Boston Scientific&#8217;s executive compensation program with the interests of shareholders and to reinforce the concept of pay for performance by providing incentives for the achievement of key business performance objectives which are critical to the success of Boston Scientific.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ONSG Program entails the grant of Restricted Stock Units, and the program shall be administered, under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;2011 LTIP&#8221;).  Terms not explicitly defined in this ONSG Program document but defined in the 2011 LTIP shall have the same meaning as in the 2011 LTIP.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Eligible Participants</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ONSG Program covers members of the Executive Committee on the date that awards are granted under the ONSG Program as determined and, in the amounts, established by the Executive Compensation and Human Resources Committee of the Board of Directors (the &#8220;Committee&#8221;).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Performance Share Units </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restricted Stock Units awarded under the ONSG Program (the &#8220;Performance Share Units&#8221;) shall vest only upon satisfaction of both the performance criteria described in this Section III and the payment eligibility criteria described in Section V.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance criteria are based on Boston Scientific&#8217;s achievement of the 2025 - 2027 financial plan performance for Organic Net Sales Growth. Organic Net Sales Growth will be measured over a three-year performance period beginning January 1, 2025</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ending on December 31, 2027. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Performance Share Units as to which the performance criteria under this ONSG Program shall be determined to have been satisfied will be in a range of 0% to 200% of the target number of Performance Share Units awarded to the participant.</font></div><div style="padding-left:72pt;text-indent:-54pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the end of the Performance Period, the Committee shall determine the number of Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied, which determination shall be final and binding.  Shares of Common Stock will be delivered or otherwise made available to the participant no later than March 15, 2028 in settlement of the Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied if and to the extent the payment eligibility criteria of Section V below are also satisfied.  Any Performance Share Units as to which the performance criteria of this Section III have not been satisfied shall be forfeited in their entirety</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Definitions</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Full month&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means 16 or more days </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Organic Net Sales Growth (ONSG)&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">excludes from reported net sales the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Partial month&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means less than 16 days</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the three-year period commencing January 1, 2025 and ending on December 31, 2027.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Payment Eligibility Criteria</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth below with respect to a Change in Control, no Performance Share Units shall vest prior to the end of the Performance Period (December 31, 2027). </font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.027%"><tr><td style="width:1.0%"></td><td style="width:34.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="image1a.jpg" src="image1a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Organic Net Sales Growth Performance Share Program</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(&#8220;ONSG Program&#8221;)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1, 2025 - December 31, 2027</font></div></td></tr></table></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with Boston Scientific and its Affiliates (the &#8220;Company&#8221;) terminates before the last day of the Performance Period, all of his or her Performance Share Units shall be forfeited in their entirety except as set forth below.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants on military, sick or other bona fide leave of absence on December 31, 2027 will not be deemed to have terminated employment with the Company if such absence does not exceed 180 days or, if longer, the period the participant retains the right by statute or by contract to return to employment with the Company. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of any separate Change in Control or similar agreement to which a participant is bound, if there is a Change in Control after December 31, 2025 but before the end of the Performance Period, shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2027, as determined by the Committee immediately prior to the consummation of the Change in Control.  Such issuance shall occur within 70 days of the effective date of the Change in Control, on a prorated basis.  The number of shares to be issued on a prorated basis shall be determined as follows&#58; (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months during the Performance Period, rounded up to the nearest whole month&#47;36)).  The number of prorated shares to be issued to the participant, if any, will be approved by the Committee at its next regular meeting.  In the event a Change in Control occurs prior to January 1, 2026, the Performance Share Units will be forfeited in their entirety.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with the Company terminates due to Retirement after December 31, 2025 but before the end of the Performance Period, the participant will continue to be eligible to vest in a prorated number of Performance Share Units and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied at the end of the Performance Period, but no later than March 15, 2028, on a prorated basis using the effective date of the participant&#8217;s termination of employment. The number of shares to be issued on a prorated basis shall be determined as follows&#58; (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months worked during the Performance Period, rounded up to nearest whole month) &#47; 36)).  The number of prorated shares, if any, to be issued to the participant will be approved by the Committee at its regular meeting next following the date of the participant&#8217;s employment termination. In the event a participant&#8217;s employment with the Company terminates due to Retirement prior to January 1, 2026, the Performance Share Units will be forfeited in their entirety.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with the Company terminates due to death or Disability before the end of the Performance Period, the participant will continue to be eligible to vest in all of his or her Performance Share Units and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this ONSG Program have been satisfied at the end of the Performance Period, but no later than March 15, 2028. The number of shares, if any, to be issued to the participant will be approved by the Committee at its regular meeting next following the date of the participant&#8217;s employment termination.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Termination, Suspension or Modification and Interpretation of the ONSG Program</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee has sole authority over administration and interpretation of the ONSG Program.  The Committee hopes and expects to continue the ONSG Program in effect but retains its right to exercise discretion as it sees fit, including to prospectively terminate, suspend or modify the ONSG program or criteria for eligible participation in future years.  If suspended, the Committee may reinstate with or without modification all or part of the ONSG Program or criteria for eligible participation. However, no amendment of the ONSG Program after the grant date may materially and adversely impair a participant&#8217;s rights under awards made pursuant to the ONSG Program without the participant&#8217;s consent unless the amendment is necessary or desirable to facilitate compliance with applicable law, as determined in the sole discretion of the Committee. The Committee reserves the exclusive right to determine eligibility to participate in this ONSG Program and to interpret all applicable terms and conditions.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Recoupment Policy</font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="padding-right:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div><div style="padding-right:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.027%"><tr><td style="width:1.0%"></td><td style="width:34.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="image1a.jpg" src="image1a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;text-indent:89.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)</font><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Organic Net Sales Growth Performance Share Program</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(&#8220;ONSG Program&#8221;)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Performance Period January 1, 2025 - December 31, 2027</font></div></td></tr></table></div></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  To the extent permitted by governing law, the Board, in its discretion, may seek Recovery of Performance Share Units granted to a Current Executive Committee Member or Former Executive Committee Member if, in the judgment of the Board, such Executive Committee Member, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">while serving in capacity as a Current Executive Committee Member,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> commits misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The following terms shall have the meaning set forth below&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)          &#34;Current Executive Committee Member&#34; means any individual currently designated as a corporate officer of the Company who is in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)          &#34;Executive Committee Member&#34; means any Current Executive Committee Member or Former Executive Committee Member.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)          &#34;Former Executive Officer&#34; means any individual previously (but not currently) designated as a corporate officer of the Company who was in an organizational job level of E-4 or E-5 (or any equivalent level under any future organizational framework).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)          &#34;Recovery&#34; means the forfeiture or cancellation of unvested Performance Share Units.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recoupment Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Performance Share Units and any compensation associated therewith are subject to forfeiture, recovery by the Company or other action pursuant to any compensation recovery policy adopted by the Board or the Committee in effect from time to time, which includes but is not limited to the Company&#8217;s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board or the Committee including in response to the requirements of Section 10D of the Securities Exchange Act of 1934, as amended, the U.S. Securities and Exchange Commission&#8217;s final rules thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing or as otherwise required by law.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Other</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This document sets forth the terms of the ONSG Program and is not intended to be a contract or employment agreement between the participant and the Company.  As applicable, it is understood that both the participant and the Company have the right to terminate the participant&#8217;s employment with the Company at any time, with or without cause and with or without notice, in acknowledgement of the fact that their employment relationship is &#8220;at will.&#8221; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent section 409A of the Internal Revenue Code (&#8220;Code&#8221;) applies to any award under this ONSG Program, the award shall be interpreted in a manner consistent with Code section 409A.  Where section 409A applies, in the case of any payment made on termination of employment, a termination of employment shall not be deemed to have occurred unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code section 409A and, for purposes of any such provision, references to a &#8220;termination,&#8221; &#8220;termination of employment,&#8221; or like terms shall mean &#8220;separation from service.&#8221;  Where section 409A applies, in the case of a payment made upon a Change in Control, a Change in Control shall not be deemed to have occurred unless there is a change in the ownership or effective control of Boston Scientific, or in the ownership of a substantial portion of the assets of Boston Scientific, as defined in Code section 409A.  Where required by section 409A in the case of a specified employee (as determined under Code section 409A), payments on termination shall be made on the first business day of the seventh month following termination.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font><br></font></div><div style="padding-left:2.15pt;padding-right:2.15pt;text-align:center"><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>bsx-20241119.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:718a6bdc-2f9f-4ecc-8b54-735e7ddf318c,g:e6f73f66-2914-4150-8689-91de50b771f2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bsx="http://www.bostonscientific.com/20241119" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bostonscientific.com/20241119">
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bsx-20241119_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bsx-20241119_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bsx-20241119_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverDocument" roleURI="http://www.bostonscientific.com/role/CoverDocument">
        <link:definition>0000001 - Document - Cover Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bsx_SeniorNotedue2027Member" abstract="true" name="SeniorNotedue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>bsx-20241119_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:718a6bdc-2f9f-4ecc-8b54-735e7ddf318c,g:e6f73f66-2914-4150-8689-91de50b771f2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/CoverDocument" xlink:type="simple" xlink:href="bsx-20241119.xsd#CoverDocument"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/CoverDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_27f73201-80b4-4b7b-b257-e92764349d9c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntitiesTable_27f73201-80b4-4b7b-b257-e92764349d9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6059a5c2-6684-435a-88c1-d3933e5cfbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_27f73201-80b4-4b7b-b257-e92764349d9c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6059a5c2-6684-435a-88c1-d3933e5cfbcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6059a5c2-6684-435a-88c1-d3933e5cfbcf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6059a5c2-6684-435a-88c1-d3933e5cfbcf" xlink:to="loc_us-gaap_ClassOfStockDomain_6059a5c2-6684-435a-88c1-d3933e5cfbcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1177a329-14d3-45d7-a655-808014c547ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6059a5c2-6684-435a-88c1-d3933e5cfbcf" xlink:to="loc_us-gaap_ClassOfStockDomain_1177a329-14d3-45d7-a655-808014c547ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_59781d77-0e97-4646-bc56-0ff1787a303b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1177a329-14d3-45d7-a655-808014c547ab" xlink:to="loc_us-gaap_CommonStockMember_59781d77-0e97-4646-bc56-0ff1787a303b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SeniorNotedue2027Member_d838f0c2-0566-4783-bc62-47a63bb93e98" xlink:href="bsx-20241119.xsd#bsx_SeniorNotedue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1177a329-14d3-45d7-a655-808014c547ab" xlink:to="loc_bsx_SeniorNotedue2027Member_d838f0c2-0566-4783-bc62-47a63bb93e98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ec027655-6578-489b-a233-0a15b61516be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_DocumentType_ec027655-6578-489b-a233-0a15b61516be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0a87de1a-2509-4055-9fd6-683fb50b4f43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_DocumentPeriodEndDate_0a87de1a-2509-4055-9fd6-683fb50b4f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_26521c79-b235-497c-ac1d-f78198a261e1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityRegistrantName_26521c79-b235-497c-ac1d-f78198a261e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d1468677-32d9-4f8f-876a-df0a689964ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_AmendmentFlag_d1468677-32d9-4f8f-876a-df0a689964ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d3c52e79-6424-44f6-8669-93a189226ad4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d3c52e79-6424-44f6-8669-93a189226ad4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b2dd265d-5773-488d-89f0-cf81ab6c041b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityFileNumber_b2dd265d-5773-488d-89f0-cf81ab6c041b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1d4e5c75-ebf9-4acf-88e9-c4a8db050cbb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityTaxIdentificationNumber_1d4e5c75-ebf9-4acf-88e9-c4a8db050cbb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1c1b2060-a88e-44c4-bcf0-b96abaac5e65" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityAddressAddressLine1_1c1b2060-a88e-44c4-bcf0-b96abaac5e65" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0ede0332-9318-4e09-8de6-030528ac0603" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityAddressCityOrTown_0ede0332-9318-4e09-8de6-030528ac0603" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_34070375-b76b-4419-914f-e627451ecb42" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityAddressStateOrProvince_34070375-b76b-4419-914f-e627451ecb42" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b42459fd-6b0e-4c77-b3cd-96aa36307c00" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityAddressPostalZipCode_b42459fd-6b0e-4c77-b3cd-96aa36307c00" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_23853b9d-3cfd-49a2-9b7d-c85f0642f0f0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_CityAreaCode_23853b9d-3cfd-49a2-9b7d-c85f0642f0f0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d8ce4de1-4204-47f6-a90a-e4ee15f8d4f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_LocalPhoneNumber_d8ce4de1-4204-47f6-a90a-e4ee15f8d4f7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_9f8e5b3a-e19b-4fd5-bb67-896687678fc3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_WrittenCommunications_9f8e5b3a-e19b-4fd5-bb67-896687678fc3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_c06fae6c-d3fd-4038-8eba-4acf1de82e57" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_SolicitingMaterial_c06fae6c-d3fd-4038-8eba-4acf1de82e57" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_d81f9857-edaf-4228-a2f5-8d92ac44f59f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_PreCommencementTenderOffer_d81f9857-edaf-4228-a2f5-8d92ac44f59f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_689699ba-5411-4618-b0cf-b97fb753dc18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_689699ba-5411-4618-b0cf-b97fb753dc18" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_83084ea0-58d4-4225-8e38-1764e2aa19d5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_Security12bTitle_83084ea0-58d4-4225-8e38-1764e2aa19d5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1cda11d1-637f-416f-aa40-6d51a0050a69" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_TradingSymbol_1cda11d1-637f-416f-aa40-6d51a0050a69" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cdfe7827-ed7e-400e-86bd-07979dcd0726" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_SecurityExchangeName_cdfe7827-ed7e-400e-86bd-07979dcd0726" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c15282c0-82b8-4bd0-961c-7013f45ee5c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityEmergingGrowthCompany_c15282c0-82b8-4bd0-961c-7013f45ee5c9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fd0fab21-fd1f-48d6-af30-fcf6b475e089" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityCentralIndexKey_fd0fab21-fd1f-48d6-af30-fcf6b475e089" xlink:type="arc" order="21"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>bsx-20241119_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:718a6bdc-2f9f-4ecc-8b54-735e7ddf318c,g:e6f73f66-2914-4150-8689-91de50b771f2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityInformationLineItems_c99b3a5e-2bbb-436a-a8e3-11f4970e69af_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2dad352e-d44b-4d21-a1aa-d6e9a2a71645_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e39342f5-b1ef-44f3-885a-a475d8821597_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_d59310f9-e026-47c6-8459-ea07c3783bc8_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_20568691-c26b-4278-be8e-420aea1d1233_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_7caebaf1-6004-4fdb-ac99-13855885bc8c_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7b1571e7-3533-4b92-b9b7-87072f7e96c4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0a325510-a881-4ed4-ac8e-f8b96e314b1a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_37b40303-4006-42cc-9ff0-df59a7bf4ae6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SeniorNotedue2027Member_e6a5d3db-1efb-4c1d-b402-89d2c8b7ea2e_terseLabel_en-US" xlink:label="lab_bsx_SeniorNotedue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Note due 2027 [Member]</link:label>
    <link:label id="lab_bsx_SeniorNotedue2027Member_label_en-US" xlink:label="lab_bsx_SeniorNotedue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Note due 2027 [Member]</link:label>
    <link:label id="lab_bsx_SeniorNotedue2027Member_documentation_en-US" xlink:label="lab_bsx_SeniorNotedue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Note due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SeniorNotedue2027Member" xlink:href="bsx-20241119.xsd#bsx_SeniorNotedue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SeniorNotedue2027Member" xlink:to="lab_bsx_SeniorNotedue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2df366da-1f18-4ab8-8ba8-b5959f53a2a7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4e2efde6-8634-40eb-95b5-71759aa30e2d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6cb503ca-5ccf-4f46-86b5-4b3515fc50f8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_d6071a98-5629-48c5-9143-0cd41c999b17_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_221969e6-3fcf-4869-bd56-f143bf5cea51_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_80ba1337-0aa2-4e4f-9c68-ff8728af35a0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1d3f2c10-cb12-4003-a9fd-a7c5bc23a68b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ae042c4d-1458-48ff-a11e-29d3da30305a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_3e8a91e1-4782-4bf5-a547-475c71193b18_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f14573ca-b6e0-40ac-9dcf-afe631393155_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ec558339-56bd-43b7-be98-c518660c6d29_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b88c83e7-afb8-40f1-b8c2-7762ca1811ba_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cac94f09-691a-490d-af3e-8d591fa9778f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_14b7f37e-31a3-489a-9e24-9d0cb320cbbe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_33a10e7b-533e-4ec4-abab-7d25c9431fed_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_d85b23e3-b1a7-40f2-afcd-0742581aaba6_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5f2a88fb-cd03-41fa-9cd4-d95bbb003095_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fa147ad9-7940-4d44-9300-79a4d3f4fefc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e0d56bca-9bf6-4eef-b064-4f38c0475b38_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>bsx-20241119_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:718a6bdc-2f9f-4ecc-8b54-735e7ddf318c,g:e6f73f66-2914-4150-8689-91de50b771f2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bostonscientific.com/role/CoverDocument" xlink:type="simple" xlink:href="bsx-20241119.xsd#CoverDocument"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/CoverDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5da551bb-5563-41dd-ae55-6021720ca07f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_27f73201-80b4-4b7b-b257-e92764349d9c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5da551bb-5563-41dd-ae55-6021720ca07f" xlink:to="loc_dei_EntitiesTable_27f73201-80b4-4b7b-b257-e92764349d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6059a5c2-6684-435a-88c1-d3933e5cfbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_27f73201-80b4-4b7b-b257-e92764349d9c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6059a5c2-6684-435a-88c1-d3933e5cfbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1177a329-14d3-45d7-a655-808014c547ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6059a5c2-6684-435a-88c1-d3933e5cfbcf" xlink:to="loc_us-gaap_ClassOfStockDomain_1177a329-14d3-45d7-a655-808014c547ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_59781d77-0e97-4646-bc56-0ff1787a303b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1177a329-14d3-45d7-a655-808014c547ab" xlink:to="loc_us-gaap_CommonStockMember_59781d77-0e97-4646-bc56-0ff1787a303b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SeniorNotedue2027Member_d838f0c2-0566-4783-bc62-47a63bb93e98" xlink:href="bsx-20241119.xsd#bsx_SeniorNotedue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1177a329-14d3-45d7-a655-808014c547ab" xlink:to="loc_bsx_SeniorNotedue2027Member_d838f0c2-0566-4783-bc62-47a63bb93e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_27f73201-80b4-4b7b-b257-e92764349d9c" xlink:to="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ec027655-6578-489b-a233-0a15b61516be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_DocumentType_ec027655-6578-489b-a233-0a15b61516be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0a87de1a-2509-4055-9fd6-683fb50b4f43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_DocumentPeriodEndDate_0a87de1a-2509-4055-9fd6-683fb50b4f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_26521c79-b235-497c-ac1d-f78198a261e1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityRegistrantName_26521c79-b235-497c-ac1d-f78198a261e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d1468677-32d9-4f8f-876a-df0a689964ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_AmendmentFlag_d1468677-32d9-4f8f-876a-df0a689964ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d3c52e79-6424-44f6-8669-93a189226ad4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d3c52e79-6424-44f6-8669-93a189226ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b2dd265d-5773-488d-89f0-cf81ab6c041b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityFileNumber_b2dd265d-5773-488d-89f0-cf81ab6c041b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1d4e5c75-ebf9-4acf-88e9-c4a8db050cbb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityTaxIdentificationNumber_1d4e5c75-ebf9-4acf-88e9-c4a8db050cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1c1b2060-a88e-44c4-bcf0-b96abaac5e65" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityAddressAddressLine1_1c1b2060-a88e-44c4-bcf0-b96abaac5e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0ede0332-9318-4e09-8de6-030528ac0603" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityAddressCityOrTown_0ede0332-9318-4e09-8de6-030528ac0603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_34070375-b76b-4419-914f-e627451ecb42" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityAddressStateOrProvince_34070375-b76b-4419-914f-e627451ecb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b42459fd-6b0e-4c77-b3cd-96aa36307c00" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityAddressPostalZipCode_b42459fd-6b0e-4c77-b3cd-96aa36307c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_23853b9d-3cfd-49a2-9b7d-c85f0642f0f0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_CityAreaCode_23853b9d-3cfd-49a2-9b7d-c85f0642f0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d8ce4de1-4204-47f6-a90a-e4ee15f8d4f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_LocalPhoneNumber_d8ce4de1-4204-47f6-a90a-e4ee15f8d4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_9f8e5b3a-e19b-4fd5-bb67-896687678fc3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_WrittenCommunications_9f8e5b3a-e19b-4fd5-bb67-896687678fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_c06fae6c-d3fd-4038-8eba-4acf1de82e57" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_SolicitingMaterial_c06fae6c-d3fd-4038-8eba-4acf1de82e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_d81f9857-edaf-4228-a2f5-8d92ac44f59f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_PreCommencementTenderOffer_d81f9857-edaf-4228-a2f5-8d92ac44f59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_689699ba-5411-4618-b0cf-b97fb753dc18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_689699ba-5411-4618-b0cf-b97fb753dc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_83084ea0-58d4-4225-8e38-1764e2aa19d5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_Security12bTitle_83084ea0-58d4-4225-8e38-1764e2aa19d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1cda11d1-637f-416f-aa40-6d51a0050a69" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_TradingSymbol_1cda11d1-637f-416f-aa40-6d51a0050a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cdfe7827-ed7e-400e-86bd-07979dcd0726" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_SecurityExchangeName_cdfe7827-ed7e-400e-86bd-07979dcd0726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c15282c0-82b8-4bd0-961c-7013f45ee5c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityEmergingGrowthCompany_c15282c0-82b8-4bd0-961c-7013f45ee5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fd0fab21-fd1f-48d6-af30-fcf6b475e089" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_206a12fc-54fc-4bba-92c4-84f429b24018" xlink:to="loc_dei_EntityCentralIndexKey_fd0fab21-fd1f-48d6-af30-fcf6b475e089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image1a.jpg
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M1IC!Y'<BG-'?*PSG1SS=\1C1+A'+WJ^N$CB\9X].W,=^U6_"[P'5O\BB@IC
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7A_\!3*#D36LF]H0     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image3a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image3a.jpg
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M1IC!Y'<BG-'?*PSG1SS=\1C1+A'+WJ^N$CB\9X].W,=^U6_"[P'5O\BB@IC
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7A_\!3*#D36LF]H0     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image5a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image5a.jpg
MB5!.1PT*&@H    -24A$4@   -D   !8" ,   !/C*(Y     7-21T( KLX<
MZ0    1G04U!  "QCPO\804   +04$Q41?____S\_/O[^^[N[M_?W]#0T,O+
MR]34U-[>WMC8V,;&QLC(R.3DY/[^_O;V]NGIZ<7%Q;*RLM?7U_'Q\8N+BTQ,
M3#HZ.FIJ:I24E(" @$='1T! 0(F)B=O;V_GY^>#@X'M[>SP\/#(R,IV=G?3T
M],[.SGU]?1X>'@L+"V=G9ZZNKI^?GW-S<SX^/CDY.8^/C^+BXJFIJ0   (6%
MA>WM[9:6EC\_/TA(2+2TM/KZ^OCX^*2DI"HJ*L# P/?W]_7U]5=75P0$!.OK
MZT1$1-G9V45%12TM+>_O[PH*"HB(B-;6UE)24J&AH>SL[$)"0BLK*X>'A^/C
MX[>WMQ 0$(2$A+^_OS,S,S<W-[R\O)B8F"0D)+.SLST]/0\/#Z>GIR4E)4-#
M0]K:VN?GY[6UM6%A875U=>7EY;"PL#L[.^KJZAD9&;JZNJ6EI9N;FVEI:?W]
M_71T=" @('=W=]S<W+BXN%555:BHJ']_?Q45%7IZ>C0T-&!@8,?'QQ(2$FYN
M;L/#P[Z^OL'!P?/S\QP<''!P<)65E1@8&%-34]75U34U-5Q<7!,3$_+R\DU-
M34E)2:*BHLG)R6QL;&9F9KV]O;&QL4M+2R@H**:FIN'AX9&1D6MK:X:&AHV-
MC5%14:RLK T-#1H:&GQ\?,_/S^CHZ P,#'%Q<<W-S7Y^?B<G)QL;&_#P\%]?
M7Y>7EQ$1$=+2TL+"PM'1T<S,S*"@H)Z>GJ^OKYF9F8R,C.;FYAT='9J:FC P
M,)R<G*NKJRXN+LK*RB$A(8Z.CH.#@U!04&)B8@X.#M/3TV1D9#$Q,;FYN2(B
M(H*"@DY.3E965GEY>:JJJKN[NT%!06-C8W)R<EY>7EA86).3D]W=W6]O;TI*
M2I"0D#@X. @("%U=70<'!Q<7%S8V-FUM;8&!@:.CHXJ*BE145$]/3P8&!A86
M%K:VMI*2DGAX>"8F)G9V=EI:6EM;6P   -:!7Q@   #P=%).4___________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________ )2A:$<    )<$A9<P  %Q$  !<1 <HF\S\   1M241!5'A>[9K-
MC?,L$,<C34=N@1,-4 @2C="'#QPH@@O<J.?Y\^'$V77 25Z]:R1^9HUMD8W'
M\\$,\6TRF4PFD\ED,IE,)I/)9#+Y%HK&Q)AV]<)+,-)W!UT',IP);243O'/7
MT4LA;#T9 2/=HKW7$(WJI4,H>K$LO)Z- %G& GKO<O<2ND4UF&22R62'IJ<T
M/ ,WE&11"9LD,LSU/"VP=23)@A,&'13"0EMG-R^&D@S^!551T$YW!*/ 1K+&
MR%<1@K52RZ2Z)F/I+,I52.:$#+&C,D@VE,Z"$M)+M\JN7#<:2V=<:%BA7'4]
MAS<]LXN70_D9R37-9G95FP1>".?<_4_X>GTTG9%:T_P<&,N3&C ZH?(^];O$
M9"B=!>:24J)E^F%V1<;?CC>2SH@SEH-]8**9-6:0$H\B&=+W-060E%NMTE [
M/D:Y+"=":(/T83HPAF.^^"HR4JRJY%2(D=8T_Q<9M>(Y[&+E>U ,*&^-2?MZ
MJ05AV,>RD?&<^_(]QEO?3$*(C$VC.XIM$/$/I/7!6VY[LI$)4O?RV-=0ICZ9
M?)R/7I '@'KZ/D168(Z!@$+P3BIGK'1NH (>(0B.2E&[4CF]AH)'R?3Y4_R_
MV:8-Q*O=)',,9MH/= ;O_ '<>NO#X9;:#]YW<)2N,O5&+R4D-R#M/M!9SJ!R
M*]O6E?ZPE0&EU:[[V']R3\\"_*W<M>$:]5/=^#YD1/6)G_'EO\"]*]FF,U1.
MFZ4%A0>U<<_P$J0_\3/OW/K<\%?V^>#W]M1*]TBBSY)T!LDB1WY0/QN#QS10
MVY-]?Z:S6"N4[^AYRF^04FL4\)+5]*#%9W[V5R"2JS1/8[ZO5RCNV4^6T-EQ
MDAHQ V/HMKN&])XM\CFH1@,SO&_[]"[IK!X^$35[XAK3^>\R*!I8];WM'3>^
MF,^,$H()D'?(9NKUO^6H=$5.LFL/7OI9M=R-2UCC6\L-+_WLDD!G.0<Y0YK/
MZN'U0:Z_]!:B[Z :'";JQR"94(^(WP+%H!+ZW-@_)U>N*#U/U9,1-3'GY\8>
M@THRUEB;:M!FOH0!7Q3P^'P-9J=T5L9^\76P$%4+BNBE;"V%4+(F.89]@!CX
MXGRZ6XI<R:9AH\I?VK_X7@J*J."+$7K9-&NBH-?NKX<7PJBEKMV'WHH2ZJJR
M[CH$%/A:4YZN9&0AV3 Z0ZZM<QV( -&U-+ZJ<?PL\!B4@CF2Z<^+0^G,<X.D
M!TJ+/H?(%L0'\C/R/-Z"$ ;AH2O9[<2;%9<A:RHJ1$<C'[]NOF DG5'(SH4Y
MVAB[21;+0NG&+L/A;A@_BSPO\06M+&0LUXB7,GSCL6!*(TDFLV01MVRWMPC2
MRW-JM]4,)8'8.$K4-[*LHMAU47</*C\F/:B7J\[J\<6A8(L.4HIU0AN0; R=
M$>J6$C;@6^F]LC84-5+,4^75'T-&,E5R11SV7FY,,X1:1;L>N BI?-_B1GQ:
MGSV$4,%+[O>O*UV5M%!PK]W;"P6)O)J0%M/K^849X!8GD\ED,IE,WN%V^P=#
3E$A0:1W;M@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>imagea.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imagea.jpg
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M1IC!Y'<BG-'?*PSG1SS=\1C1+A'+WJ^N$CB\9X].W,=^U6_"[P'5O\BB@IC
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7A_\!3*#D36LF]H0     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45519143354528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Document<br></strong></div></th>
<th class="th"><div>Nov. 19, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 19,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BOSTON SCIENTIFIC CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-2695240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">300 Boston Scientific Way<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Marlborough<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01752-1234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">683-4000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BSX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bsx_SeniorNotedue2027Member', window );">Senior Note due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Senior Notes due 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BSX27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bsx_SeniorNotedue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bsx_SeniorNotedue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ 4()V60=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " !0@G99^S](KNT    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " !0@G99F5R<(Q &  "<)P  $P
M        @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %""
M=EEOBRB X 0  "D5   8              " @0P(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " !0@G99GZ ;\+$"  #B#   #0
M        @ $B#0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %""=EF7BKL<
MP    !,"   +              "  ?X/  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( %""=EDWU&O^-@$  "L"   /              "  ><0  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " !0@G99)!Z;HJT   #X 0  &@
M    @ %*$@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" !0@G9999!YDAD!  #/ P  $P              @ $O$P  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"  !Y%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bsx-20241119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/CoverDocument</Role>
      <ShortName>Cover Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="bsx-20241119.htm">bsx-20241119.htm</File>
    <File>bsx-20241119.xsd</File>
    <File>bsx-20241119_def.xml</File>
    <File>bsx-20241119_lab.xml</File>
    <File>bsx-20241119_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bsx-20241119.htm": {
   "nsprefix": "bsx",
   "nsuri": "http://www.bostonscientific.com/20241119",
   "dts": {
    "inline": {
     "local": [
      "bsx-20241119.htm"
     ]
    },
    "schema": {
     "local": [
      "bsx-20241119.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "bsx-20241119_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bsx-20241119_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bsx-20241119_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 1,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 25
   },
   "report": {
    "R1": {
     "role": "http://www.bostonscientific.com/role/CoverDocument",
     "longName": "0000001 - Document - Cover Document",
     "shortName": "Cover Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bsx-20241119.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bsx-20241119.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "bsx_SeniorNotedue2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bostonscientific.com/20241119",
     "localname": "SeniorNotedue2027Member",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Note due 2027 [Member]",
        "label": "Senior Note due 2027 [Member]",
        "documentation": "Senior Note due 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0000885725-24-000081-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000885725-24-000081-xbrl.zip
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MO=4(HK-;QX[F7:-:_:4DBO9>\X"",9V$:.[DW[*=M+7-13)=(4$:=9V9U[6
MPRPLR6KJN>6[?MC]N2H^9U/@@#:E"\===E^-01(XN62W9.@OJ/>JS $5 #8+
MG:DLR)W_8UVC#J,77V\E12UH!Y&$HM PD:9/EX/QQ3LR&I^/+T9'/]K11?_3
M<# >7(S(^>4[<O%7__?SR]\N2/_JX\?!:#2XNCP@">96)/Q)^1Q<!H"19?).
M[^L ]AOUS@&'7=UBV&=B&#:S_%! SVX,\";$4J7>O_;Q6:/_62G1^ZOA1[(]
MAE.NH02T$L*!/6IK?ZSCMZ,6BU(/U'%X<3DFPXOKJ^%XY^$>?'ZWH_+ZTW#T
MZ1S('%\1,$%CL#/$J)&K(3$:)_8IN7I/QK]?'#T9&>N96L[S_AB';W1J]2,?
M_]/;H.]$>A%:$7]*ABSPPXB<J.^, O<8CPB[P3A5*!XS^[3[%:;L6B"V"XGC
M2D3&* "'W45=&W[1P$&(YEA-L^E26T+7&O-2][74N_1O),PU.F41_GJT)?S"
MY"QH. .T%_E!%VW\MY^KYB-%?-<XQ)#-'(X!H^@2GBA6@R_S]FHT!OLUZ@_
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M<#B<4VL><Q9%?-."<8AHQB;1W->_)/?YK@3^&J2:NO_K!!(>)X'G*D #H]7
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M:=HR0&9NL8-XI!HV?4!G,/>A4 &=M=W\.:@7<YF%MT=YOH@)Q9R)4L#U)&<
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M$N2 "]H@YYX7P[KRUO=BCO<N>E]WE"-ON;;/KGTJBU>\"E[AZ95[Q^O+) [
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M)]*\)S,BD 5.LX@)I ,],-Q#'!.L9$$N0:LA? GG"8@GP-[3XKP-$O "^EY
MWU>!ON+E[O@0X,9E>3LX6/MQX. #9XH[>)]6]O,^7>/$>WADO%JF9PG6?<\)
MEOA6[/2CZ/T>R"T6 *4,E[Z>4OUN912^!\*+YQFSO/ZQPPN3IM-OEV3^T N3
M:.'E!$Q.V]G!!T@ :4_?E-B=434T-,DR)5OD[HK,O'FT*/6VR.]8R]8K9XZQ
M4EYP8/5UA3X/.3-?Y&R?<F8*.8MXN)-\/6I'Y9D(6NT?+W*V/SFK"3E+''KP
M3X5[&DB!^S89:\]%T.KY5PT"Z;@_=(W'Y 88R:+2:K^C$94O9SW!@(HM?79
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M@7+/NAWQQOH1S]/H1-IG0+C>(^1\MU?G[\]]O_HZ.:P2UEDU9ISX'T%X]9+
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M;?OUZ653')]T,TZY7#=;?]L\,\QZ'5(D/+M,),1(;%"2&*' I)0%L_%?Q\]
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ME+Q3)B+)IK$?,R*1F4Y!I3G  DI@E!>!E,I(I#Q1+%(V0AO ./7LJD$-:MC
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M)+2MKN&![A*K]YK-/]\4N?IXUTSDHPC2F)JR#^DZ/Z4Q!5R2&&@C,:Z)4(Q
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M#:>06G>V!Y&FR3$&/-A%]\PX??&R33]'B()7+G(/@$=F.D!N1)KJLSQQSCI
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MA_@5Y;YA/_Q'8VOPZ>=3('2Z* 'W',YU?0* =;&(\UQ*!(_4H.E)WO1YEB4
M%]S$\]CD.IX4!'M8!AD)2%NW<.OSX5>1!U=Q@L .(O<TG + EB'@-K^DC< 1
MP$65NAV!@%W^\-W#X_&#)R;(O'W#\P"15XF:P/%?B$2:47 >(7+#\R^$3H$
M#&XQN)@#'$?!6W@:< 8TZM=IJ!8RV!-X8AE_!'Z!P57V1T2E,9R)R %+TH6]
M^A?@69POZ>J+]#+6BBX)..(+%<;X7[ST"MBW3FF+>R\N7NT#XBHM0Z&C8*9$
M I@4O-\,I@YJ$YE?29D&1]_3"\:G1]\?!K=!^U\M$WEO<4.FAKG &Y$"Q.BD
M+I:  0M$GQ0I2H5 +!NCL5@HP ^\>4$K:A/L:6F*A/ &2$X$DR)"%)\Z=F!O
MW!\1Q<I+D11(GKB&CZZ60$H*3@&_"A"8A/NQMLN40J*DP.I%WJ,CMWR#_+Q;
M2IJQ)%GCDS6B['N0;SV_0LQ=P6#N/"(B!_X1>),5ZS'Q)=J<S\/@CAAU+I!N
MADYXJ0KM_X2\B)BY=Q;!9!ED6EW&$:,?'G=\*<'R\'#?G0W@2"POI6-7]KW,
MS%( 9QPA M1P<O*G#'%!<\?Y"7'D4&0Q<'-X+$+Q'_$Q(1E:@D%I7!C22K0J
M9G-5Y)4(QHN1G#H% W\'V60,&AWP]SF>*3">U_\ZO(&R5].K$63?GL9^O'L:
M.RE<<2GKWY5*%U#;'=+4_ZV*&RF@HB4=@GB*;"Y 1F6F2U)PK:1BM1JYFO3
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MW+?8E&5"-@#4R1M)$<;M8L1A 9L'OJ-E*%$Y7\L>1=<6.S_2VV-6:%.@JQF
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M, N5:^HB+B"VCSU?IK#[T*[M]?^KU4^\$:FPING%$L3WXM.PZ"YQPI[)BSN
M66V%>WT#.\9'6U09E\4V5$)9%4]ZS?R;'63[1QIZ&9>54ZF[5S!YD <,W! #
MUS*&W43&-H8(K^YX%'AV6I6,6^7*-@TWOH'%8!W]+D"IK%)H3>E_M%7-J0*F
M26,P@'AQBN^G5I7>(=RCS+OMHY>?E#P%*M" 9(H#E9]15[I#Y]PS8'9'3KYG
M=\/QW]KQ@U6S(V=M>X]@4>NE3 O)%A=5"#P\JU<(N/2",@^!TC:[$O@'1-@8
M$:P$WA%LJ-5R>54_<+Q_IPS4W\H,U$IY\"MSAY/?_.31:[H#Y[Y^VEE]S-DV
MCGC(&!XRAH>,X2%C>,@8'C*&[U#&\#H%HM_?'&Q3L:CT2:.F^17FC>;HA*=,
MED8A./HW+X7&D5WUDNE%]4EN.L,0BNE#A5XWW?;UR\U<E80LX5Q&!0YA-1PZ
M+#V6HWJ'8-OI"!..:_.O;3_'Q@SL?@_ZAF&@P:39$ W7-@39/C8V^MP%(>\Y
M60*R86,FU[94E"'PLDZC.0X9RQQC[@&%,T9G(K69*+#LGVH2)/)2TJ#'%P<G
MU.[UX)3CT3@<^*\BO@3RQ,0-NLW.;*V:Y346G&JQD-@K=$6>U-UF@O7 [&Z(
MOT9#GJZ0>9DU40::*7W3KV[_,7A=(:S/Q;B# 580H8B-TZR@]'&U23R:*Y'K
M0.N9P67FPDZ=Y,$^U+_6?E([TMX[4&K V^[YTZMG[>P$RV27K]O;J/YGH$#F
M"EL)3@V1,P%R%-&\;Y(\,C+;U@:[5K%GQN? #251F(WZ^ \8MAK#[-"Y'4 I
M;C=FVN. J]RQD5<!5P49,JU"4!*U;)>Z<:X91;))^?!&F F;_*@WZ;]>WK*W
M)ON4VVM?B24GKR)2,PO-L",\W'0I0IM"A_V?9BFU+Y^CBT,L[<# EV]^.>>9
MF8-@[T/?]#+6BI1\Y#T7V'^,<WM?47=3DC![+RY>[8/)HP#2&+;>NOS?S.SQ
MK15!J;MY,$O4!#YP)JU*& 6_7UA<-%PV'+PKI,;1EW&H]CFU+83_*;#PDFR>
M4? BG3F!;W\AZNEXG<U-DCZ4K>7$C:.QV1\BB!V8W=FFI/XT-=B1,] K: 8X
M+38$AC9%]])ZVB8.MWKR5M;3+77Y'1!B<X3P&_;O@/0&FN[5[-@H5JG_ZX\F
M^#TEL7F14UN"3"RUL@4:./,T3(0QM31;3_,3-K- >T,R ,'<C]6D"P>A'[X[
M??2$QJ5:?H=KH$5._*Q>Q6K\M#C6("3#NVP(@/V4%@7(=Y<2K"C&L&BW8,2[
M7XI8![^(">S0S; Q7M/%AWY*1;#W\I>+\WW>KQO-&G\IX[6S['(%'H+ZLU7<
MHWJ#:;V,\09=L6]-;WIPO"MENWVMCQ\>'Y_M4NMCJMU=3>/.Q,2TY@4*#I,7
M$<U$#M6!RDI^0Q:F 24\(<>$0MH'\BVO,RUMVL9Z.,K/<)1DPX$Z*O#T<C@8
MX"5ZR0W)I\AGZR<6[+G:G>K>J:2A45BK#Z;43(OJ=K-?0X$0%4W%93S6-O.7
MY[':Z'33$9B0CDL#BR9KK8PXP(IIP:K+U$[3XL%,@Y:RH718J^_MA-Y2\_UG
M6EYBW#%9!GO.OB_C ?L?%Q# _OI#1& W4/(5&](7 -6M3A DIY"+89>Q@%:=
M$^"H(<>6P0T'A:&":86]=%.'F.$RT*1!TVC3:]N]W"M?=J6X9?FR:RI#MY9]
M)*S1;SVW6(@_^$][\6A-].5K\34UIAVB")_98J!:)5OIU.$,#%W%WDE0=]WI
M^Y4L0GV>,- =$JB_B"7(F5V0FD%"6_'5KCB]5$D!B*27M68!9#1[;9?LM"3J
M*D4^_C*,0V,N)?8;0<S(Q-()O%*<>E<3DJ>U<0+B:F!7?:,*6T,>=P&+O@:?
M$:W]L7ZC%.#^Q7U'_40PI,P/*?-#ROR0,C^DS \I\UM-F?\&5:RWI=WL.IV1
MSF&M*YK&A3;\/NL^6]6^4*\(&]%Z;4M]R2,: KWACK%K&DW-B?CWRC=@&ZMA
M#H%K1H?:>]F/#%M]<>*.R;U^K\IT9')W[J=<5KI&BYG4W(20FJ%C/UBZA9N>
MT?NL1V.3%G#<I&I%([AZ![@?OCMY\"3Z3 W@^*FJF=OF[=]H%MOOP9OGO[7:
MM\$)#OD5F]+N.]O-_/E.=%O;W'53G\-9ZP;?VYNS[&[?F)?EFK>XOO2I"I*J
MI_L;H>':^+05;5TSP?UNRX2::U#F.@ZWR_C9[/9]X%X[V'9'6V8PFPJV 0G6
M(P%2X-;##IBYOV!LI.Q],!CJN7KVXLAK C$^/EC ZG,W%'@BP9RA(?+ ?BH]
MET(0W!S8NFXJ1N%IP(>8"L9E6]TO7OW*MV&N<*$Q::LK7WJ![87YK4<CO/UT
M0-,>-/6,J"TR)^X:LM;<\UJ-H=[&<Q3< $ W8V%D1R[B!$IL.6J]9*W1OP-*
M=*/$/P#FV,3U'-L(&X3HCB (9?P;.YHB%Q]DVFY?5_$ YC/4MDP*P)D.74H%
M\E(D!:I3=7\SI9K@JQ8B0GRA&3FP2 SFDBLQQ58H?UE0-89"-JM/ZU[N@ZL8
M%G6/FJ$IZ$V0LUF]L0.H>:OQC'K39%BZ$;_!V$5'6&?HK[TY N4VV$*Q&PK-
M\ ",8 8$C-F'Y0#U/UR2!([TFFF1S;G!=0)'8Z?$5,NM'10S'$3M(&R]J"_C
MMTK,W=A );08\\-,0L"&<S2=L5#L]>M!?UAYL'[+;?)O;/5T-^X\42P:!<T^
M@G+2%EI2[1G'&Y2E]J?"#.Q[4^12:#':,RE]%SN0=\45\QVB&?7,G,H4N;K.
M[;D:.E[E(N"8QGD\S8,HGDXEII_&5+'G<@5&7B&IK1ZU3\7A!\I6+M<?N?'D
M0<3NZ 6Z]4#O@+LG*N5:5B,F$T$1/S>W0]BQX%2(>I-!/!\Y7>OKZOGWTT1%
M2_C//%\DS_X?4$L#!!0    ( %""=EDB#ZF5<1L  'H# 0 5    97@Q,#(M
M,C R-71S<G!L86XN:'1M[3UK5QLYEM_W5VB3F1[8,8X?& AD<@XA=(?9?M#
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M7S$E8,V3F2"Z^]:H\<,B[*EL6)F NF6_G"60*N%/<M"!D"YX=)T1Z;TYA\7
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M\Y8_Y#IU,[9EJN(6K.?[8DFE_SUO8.D;T?[# DMM&A73QA!3NY7]NYU&F+:
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M%WR7GGAE1M*\Z2M_ O\9F3!X__]02P,$%     @ 4()V62:5?W!"$@  "G$
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M  !B<W@M,C R-#$Q,3DN>'-D4$L! A0#%     @ 4()V6?C:^ZY>"   (#P
M !0              ( !9QP  &)S>"TR,#(T,3$Q.5]D968N>&UL4$L! A0#
M%     @ 4()V6<W<UD*D#   +FL  !0              ( !]R0  &)S>"TR
M,#(T,3$Q.5]L86(N>&UL4$L! A0#%     @ 4()V6?CFOXL*"   NSX  !0
M             ( !S3$  &)S>"TR,#(T,3$Q.5]P<F4N>&UL4$L! A0#%
M  @ 4()V62?MA*<X)0  VRD! !T              ( !"3H  &5X,3 Q+3(P
M,C5A;FYU86QB;VYU<W!L86XN:'1M4$L! A0#%     @ 4()V62(/J95Q&P
M>@,! !4              ( !?%\  &5X,3 R+3(P,C5T<W)P;&%N+FAT;5!+
M 0(4 Q0    ( %""=EDFE7]P0A(   IQ   >              "  2![  !E
M>#$P,RTR,#(U;W)G86YI8VYE='-A;&5S<"YH=&U02P4&      @ "  < @
&GHT

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>bsx-20241119_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bsx="http://www.bostonscientific.com/20241119"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bsx-20241119.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <startDate>2024-11-19</startDate>
            <endDate>2024-11-19</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-19</startDate>
            <endDate>2024-11-19</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:SeniorNotedue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-19</startDate>
            <endDate>2024-11-19</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-24">0000885725</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-25">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-11-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">BOSTON SCIENTIFIC CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">1-11083</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">04-2695240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">300 Boston Scientific Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Marlborough</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">01752-1234</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">508</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">683-4000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-17">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-18">BSX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-19">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-20">0.625% Senior Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-21">BSX27</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-22">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
